Lancet neurology
The most recent articles from:
Lancet Neurol
-
Randomized Controlled Trial Multicenter Study
Safety and efficacy of rimegepant orally disintegrating tablet for the acute treatment of migraine in China and South Korea: a phase 3, double-blind, randomised, placebo-controlled trial.
No acute treatments targeting calcitonin gene-related peptide (CGRP) have been approved for use in China or South Korea. We aimed to compare the efficacy and safety of rimegepant-an orally administered small molecule CGRP antagonist-with placebo in the acute treatment of migraine among adults in these countries. ⋯ For the Chinese and Korean translations of the abstract see Supplementary Materials section.